A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- NA · SINGLE GROUP · TREATMENT · NONE
- Evidence population
- Human clinical study registration
- Participants
- 38
- Population
- ALL · 16 Years
- Duration
- 2014-02-01 to 2017-10-02
- Intervention
- Brentuximab Vedotin
- Comparator
- Not reported
- Outcomes measured
- Complete metabolic response rate (CMR) after 4 cycles of brentuximab vedotin defined as Deauville score of 1, 2 or 3 by…; Tolerability is defined in terms of absence of toxicities related to BV quantified by the CTCAE v4 criteria and dose in…; Overall objective response rate (ORR), including complete or partial metabolic response (CMR/PMR), after 4 cycles and 1…; Progression Free Survival (PFS) where progression is defined as the time from date of Cycle 1 Day 1 until documented pr…; Overall survival (OS) and cause of death. OS is defined as the time from Cycle 1 Day 1 to the date of death from any ca…; Deauville score after cycle 2 based on blinded PET2 scan — 5 years from start of treatment; Correlation of Deauville score after 2 cycles (blinded PET2) with Deauville score after 4 cycles (PET 4) — 5 years from…; Correlation of Deauville score after 2 cycles (blinded PET2) with response after 16 cycles — 5 years from start of trea…; Correlation of Deauville score after 2 cycles (blinded PET2) with overall survival — 5 years from start of treatment; Correlation of Deauville score after 2 cycles (blinded PET2) with progression-free survival — 5 years from start of tre…; CIRS-G profile in the study population assessed at baseline — 5 years from start of treatment; Co-morbidities satisfying eligibility criteria in the study population and documented throughout the study — 5 years fr…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 80% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Frailty · 80%Title contains controlled topic terminology. Title supplies ageing or longevity context.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.